Pharma News

Potentially life-saving therapies for cancer will be accelerated into clinical trials more quickly due to a pioneering project launched by scientists and clinicians at the University of Sheffield.

By collecting samples from the portal vein -- which carries blood from the gastrointestinal tract, including from the pancreas, to the liver -- physicians can learn far more about a patients pancreatic cancer than by relying on peripheral blood from a more easily accessed vein in the arm, says a study.

Fortis Escorts Heart Institute (FEHI) has become first corporate hospital in India to get accredited by an international forum to conduct high-ethical standard research.

 Personally tailored diabetes care reduces mortality - both all-cause and diabetes-related - in women but not men, a study has found.

Scientists have reported first-ever measurements of a key neurotransmitter involved in learning with unprecedented precision in the brains of people with Parkinson's disease.

European and North American blood pressure guidelines, issued last year, may actually increase the stroke risk if adapted for Asian patients, particularly the elderly, experts have warned.

The number of adolescent deaths from AIDS has tripled over the last 15 years, most of the patients having acquired the disease when they were infants, according to new data released on Friday by Unicef.

[adsense:336x280:8701650588]

In a setback to Cipla, the Delhi High Court on Friday held that the Indian drug major was infringing Swiss pharmaceutical company Hoffman-La Roche's patent in lung cancer drug erlotinib hydrochloride, sold under the name of Tarceva.

Takeda Pharmaceutical Company Limited announced that the U.S. Food and Drug Administration (FDA) has approved NINLARO® (ixazomib) capsules, the first and only oral proteasome inhibitor, indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO is a once-weekly pill.

Novartis announced  that the European Commission (EC) has approved EntrestoTM (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF). Entresto is a twice a day tablet and has a unique mode of action which is thought to reduce the strain on the failing heart.